193 related articles for article (PubMed ID: 25879875)
1. Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer.
Yamamoto T; Mori T; Sawada M; Matsushima H; Ito F; Akiyama M; Kitawaki J
BMC Cancer; 2015 Apr; 15():275. PubMed ID: 25879875
[TBL] [Abstract][Full Text] [Related]
2. Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth.
Fournier G; Cabaud O; Josselin E; Chaix A; Adélaïde J; Isnardon D; Restouin A; Castellano R; Dubreuil P; Chaffanet M; Birnbaum D; Lopez M
Oncogene; 2011 Sep; 30(36):3862-74. PubMed ID: 21478912
[TBL] [Abstract][Full Text] [Related]
3. Disrupted interaction between CFTR and AF-6/afadin aggravates malignant phenotypes of colon cancer.
Sun TT; Wang Y; Cheng H; Xiao HZ; Xiang JJ; Zhang JT; Yu SB; Martin TA; Ye L; Tsang LL; Jiang WG; Xiaohua J; Chan HC
Biochim Biophys Acta; 2014 Mar; 1843(3):618-28. PubMed ID: 24373847
[TBL] [Abstract][Full Text] [Related]
4. CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.
Yang M; Li Y; Ruan Y; Lu Y; Lin D; Xie Y; Dong B; Dang Q; Quan C
Mol Cell Biochem; 2018 Jun; 443(1-2):169-180. PubMed ID: 29159771
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways.
Li Z; Min W; Gou J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1001-11. PubMed ID: 24036847
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
7. PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma.
Zhou JW; Tang JJ; Sun W; Wang H
Mol Med; 2019 Mar; 25(1):11. PubMed ID: 30925862
[TBL] [Abstract][Full Text] [Related]
8. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
9. KCC1 gene advances cell invasion ability by regulating ERK signaling pathway in endometrial cancer HEC-1B cell line.
Shang C; Lu YM; Meng LR
Int J Gynecol Cancer; 2011 Jul; 21(5):795-9. PubMed ID: 21666489
[TBL] [Abstract][Full Text] [Related]
10. Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation.
Liu Y; Lv L; Xiao W; Gong C; Yin J; Wang D; Sheng H
J Huazhong Univ Sci Technolog Med Sci; 2011 Jun; 31(3):365. PubMed ID: 21671179
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells.
Keeratichamroen S; Lirdprapamongkol K; Svasti J
Oncol Rep; 2018 Apr; 39(4):1765-1774. PubMed ID: 29436672
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of Sam68 expression in endometrial carcinoma.
Wang Q; Li Y; Zhou J; Liu J; Qin J; Xing F; Zhang J; Cheng J
Tumour Biol; 2015 Jun; 36(6):4509-18. PubMed ID: 25874492
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
14. LncRNA HEIH Enhances Paclitaxel-Tolerance of Endometrial Cancer Cells via Activation of MAPK Signaling Pathway.
Guo JL; Tang T; Li JH; Yang YH; Zhang L; Quan Y
Pathol Oncol Res; 2020 Jul; 26(3):1757-1766. PubMed ID: 31650338
[TBL] [Abstract][Full Text] [Related]
15. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE
Gynecol Oncol; 2018 Mar; 148(3):576-584. PubMed ID: 29395309
[TBL] [Abstract][Full Text] [Related]
16. BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway.
Wang F; Chen Q; Huang G; Guo X; Li N; Li Y; Li B
BMC Cancer; 2018 Nov; 18(1):1128. PubMed ID: 30445932
[TBL] [Abstract][Full Text] [Related]
17. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
18. Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer.
Zhao N; Guo Y; Liu P; Chen Y; Wang Y
Arch Gynecol Obstet; 2022 Mar; 305(3):693-701. PubMed ID: 34476599
[TBL] [Abstract][Full Text] [Related]
19. Long Non-Coding RNA BANCR Promotes Endometrial Cancer Cell Proliferation and Invasion by Regulating MMP2 and MMP1 via ERK/MAPK Signaling Pathway.
Wang D; Wang D; Wang N; Long Z; Ren X
Cell Physiol Biochem; 2016; 40(3-4):644-656. PubMed ID: 27898420
[TBL] [Abstract][Full Text] [Related]
20. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
